BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24766281)

  • 1. Lineage-dependent skewing of loss of heterozygosity (LOH) of KRAS gene in a case of juvenile myelomonocytic leukemia.
    Tokuda K; Eguchi-Ishimae M; Iwabuki H; Kawakami S; Tauchi H; Ishii E; Eguchi M
    Eur J Haematol; 2015 Feb; 94(2):177-81. PubMed ID: 24766281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive transformation of juvenile myelomonocytic leukemia associated with duplication of oncogenic KRAS due to acquired uniparental disomy.
    Kato M; Yasui N; Seki M; Kishimoto H; Sato-Otsubo A; Hasegawa D; Kiyokawa N; Hanada R; Ogawa S; Manabe A; Takita J; Koh K
    J Pediatr; 2013 Jun; 162(6):1285-8, 1288.e1. PubMed ID: 23403250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.
    Sakashita K; Kato I; Daifu T; Saida S; Hiramatsu H; Nishinaka Y; Ebihara Y; Ma F; Matsuda K; Saito S; Hirabayashi K; Kurata T; Uyen LT; Nakazawa Y; Tsuji K; Heike T; Nakahata T; Koike K
    Leukemia; 2015 Mar; 29(3):606-14. PubMed ID: 25102944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.
    Zhang J; Wang J; Liu Y; Sidik H; Young KH; Lodish HF; Fleming MD
    Blood; 2009 Feb; 113(6):1304-14. PubMed ID: 19066392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia.
    Yoshimi A; Kamachi Y; Imai K; Watanabe N; Nakadate H; Kanazawa T; Ozono S; Kobayashi R; Yoshida M; Kobayashi C; Hama A; Muramatsu H; Sasahara Y; Jakob M; Morio T; Ehl S; Manabe A; Niemeyer C; Kojima S
    Pediatr Blood Cancer; 2013 May; 60(5):836-41. PubMed ID: 23023736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.
    Park HD; Lee SH; Sung KW; Koo HH; Jung NG; Cho B; Kim HK; Park IA; Lee KO; Ki CS; Kim SH; Yoo KH; Kim HJ
    Ann Hematol; 2012 Apr; 91(4):511-7. PubMed ID: 21901340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy.
    Muraoka M; Okuma C; Kanamitsu K; Ishida H; Kanazawa Y; Washio K; Seki M; Kato M; Takita J; Sato Y; Ogawa S; Tsukahara H; Oda M; Shimada A
    J Hum Genet; 2016 Jun; 61(6):523-6. PubMed ID: 26911351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Juvenile myelomonocytic leukemia in a 16-year-old with Noonan syndrome: case report.
    Ortiz MV; Skoda-Smith S; Rauen KA; Allan RW; Slayton WB
    J Pediatr Hematol Oncol; 2012 Oct; 34(7):569-72. PubMed ID: 22510777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Juvenile myelomonocytic leukemias].
    Lachenaud J; Strullu M; Baruchel A; Cavé H
    Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blastic transformation of juvenile myelomonocytic leukemia caused by the copy number gain of oncogenic KRAS.
    Osumi T; Kato M; Ouchi-Uchiyama M; Tomizawa D; Kataoka K; Fujii Y; Seki M; Takita J; Ogawa S; Uchiyama T; Ohki K; Kiyokawa N
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia.
    Strullu M; Caye A; Cassinat B; Fenneteau O; Touzot F; Blauwblomme T; Rodriguez R; Latour S; Petit A; Barlogis V; Galambrun C; Leblanc T; Baruchel A; Chomienne C; Cavé H
    Leukemia; 2013 Dec; 27(12):2404-7. PubMed ID: 23823657
    [No Abstract]   [Full Text] [Related]  

  • 12. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML).
    Flotho C; Valcamonica S; Mach-Pascual S; Schmahl G; Corral L; Ritterbach J; Hasle H; Aricò M; Biondi A; Niemeyer CM
    Leukemia; 1999 Jan; 13(1):32-7. PubMed ID: 10049057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
    De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
    Locatelli F; Algeri M; Merli P; Strocchio L
    Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
    Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
    Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.
    Loh ML; Sakai DS; Flotho C; Kang M; Fliegauf M; Archambeault S; Mullighan CG; Chen L; Bergstraesser E; Bueso-Ramos CE; Emanuel PD; Hasle H; Issa JP; van den Heuvel-Eibrink MM; Locatelli F; Stary J; Trebo M; Wlodarski M; Zecca M; Shannon KM; Niemeyer CM
    Blood; 2009 Aug; 114(9):1859-63. PubMed ID: 19571318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. After 95 years, it's time to eRASe JMML.
    Meynier S; Rieux-Laucat F
    Blood Rev; 2020 Sep; 43():100652. PubMed ID: 31980238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.
    Melo-Cardenas J; Xu Y; Wei J; Tan C; Kong S; Gao B; Montauti E; Kirsammer G; Licht JD; Yu J; Ji P; Crispino JD; Fang D
    Blood; 2018 Jul; 132(4):423-434. PubMed ID: 29844011
    [No Abstract]   [Full Text] [Related]  

  • 20. Aggressive congenital juvenile myelomonocytic leukemia associated with somatic KRAS p.G13D mutation and concurrent germline IGF1R duplication.
    Kothari A; Hulbert ML; Cottrell CE; Nguyen TT
    Leuk Lymphoma; 2015 Apr; 56(4):1175-8. PubMed ID: 25110823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.